RT Journal Article
SR Electronic
T1 The Ontario Neurodegenerative Disease Research Initiative
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.30.20165456
DO 10.1101/2020.07.30.20165456
A1 Kelly M. Sunderland
A1 Derek Beaton
A1 Stephen R. Arnott
A1 Peter Kleinstiver
A1 Donna Kwan
A1 Jane M. Lawrence-Dewar
A1 Joel Ramirez
A1 Brian Tan
A1 Robert Bartha
A1 Sandra E. Black
A1 Michael Borrie
A1 Donald Brien
A1 Leanne K. Casaubon
A1 Brian C. Coe
A1 Benjamin Cornish
A1 Allison A. Dilliott
A1 Dar Dowlatshahi
A1 Elizabeth Finger
A1 Corinne Fischer
A1 Andrew Frank
A1 Julia Fraser
A1 Morris Freedman
A1 Barry Greenberg
A1 David A. Grimes
A1 Ayman Hassan
A1 Wendy Hatch
A1 Robert A. Hegele
A1 Christopher Hudson
A1 Mandar Jog
A1 Sanjeev Kumar
A1 Anthony Lang
A1 Brian Levine
A1 Wendy Lou
A1 Jennifer Mandzia
A1 Connie Marras
A1 William McIlroy
A1 Manuel Montero-Odasso
A1 David G. Munoz
A1 Douglas P. Munoz
A1 Joseph B. Orange
A1 David S. Park
A1 Stephen H. Pasternak
A1 Frederico Pieruccini- Faria
A1 Tarek K. Rajji
A1 Angela C. Roberts
A1 John F. Robinson
A1 Ekaterina Rogaeva
A1 Demetrios J. Sahlas
A1 Gustavo Saposnik
A1 Christopher J.M. Scott
A1 Dallas Seitz
A1 Christen Shoesmith
A1 Thomas D.L. Steeves
A1 Michael J. Strong
A1 Stephen C. Strother
A1 Richard H. Swartz
A1 Sean Symons
A1 David F. Tang-Wai
A1 Maria Carmela Tartaglia
A1 Angela K. Troyer
A1 John Turnbull
A1 Lorne Zinman
A1 Paula M. McLaughlin
A1 Mario Masellis
A1 Malcolm A. Binns
A1 on behalf of ONDRI Investigators
YR 2020
UL http://medrxiv.org/content/early/2020/08/02/2020.07.30.20165456.abstract
AB Objective In individuals over the age of 65, concomitant neurodegenerative pathologies contribute to cognitive and/or motor decline and can be aggravated by cerebrovascular disease, but our understanding of how these pathologies synergize to produce the decline represents an important knowledge gap. The Ontario Neurodegenerative Disease Research Initiative (ONDRI), a multi-site, longitudinal, observational cohort study, recruited participants across multiple prevalent neurodegenerative diseases and cerebrovascular disease, collecting a wide array of data and thus allowing for deep investigation into common and unique phenotypes. This paper describes baseline features of the ONDRI cohort, understanding of which is essential when conducting analyses or interpreting results.Methods Five disease cohorts were recruited: Alzheimer’s disease/amnestic mild cognitive impairment (AD/MCI), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Parkinson’s disease (PD), and cerebrovascular disease (CVD). Assessment platforms included clinical, neuropsychology, eye tracking, gait and balance, neuroimaging, retinal imaging, genomics, and pathology. We describe recruitment, data collection, and data curation protocols, and provide a summary of ONDRI baseline characteristics.Results 520 participants were enrolled. Most participants were in the early stages of disease progression. Participants had a median age of 69 years, a median Montreal Cognitive Assessment score of 25, a median percent of independence of 100 for basic activities of daily living, and a median of 93 for instrumental activities. Variation between disease cohorts existed for age, level of cognition, and geographic location.Conclusion ONDRI data will enable exploration into unique and shared pathological mechanisms contributing to cognitive and motor decline across the spectrum of neurodegenerative diseases.Competing Interest StatementSHP is a consultant for Zywie Bio LLC, working on a disease modifying treatment for Parkinson's disease; SCS is the Chief Scientific Officer of ADMdx, a medical diagnostics company specializing in neuroimaging of neurodegenerative disorders.Funding StatementThis research was conducted with the support of the Ontario Brain Institute, an independent non-profit corporation, funded partially by the Ontario Government. Matching funds were provided by participating hospital and research institute foundations, including the Baycrest Foundation, Bruyère Research Institute, Centre for Addiction and Mental Health Foundation, London Health Sciences Foundation, McMaster University Faculty of Health Sciences, Ottawa Brain and Mind Research Institute, Queen’s University Faculty of Health Sciences, Providence Care (Kingston), St. Michael’s Hospital, Sunnybrook Health Sciences Foundation, the Thunder Bay Regional Health Sciences Centre, the University of Ottawa Faculty of Medicine, and the Windsor/Essex County ALS Association. Also, the Temerty Family Foundation provided the major infrastructure matching funds.In addition, CF is supported by Vielight Inc, Hoffman LaRoche, Brain Canada, PCORI and the Heather and Eric Donnelly Endowment; MJ is supported by CIHR, Parkinson Society Canada, MITACS, OCE, Research Council of Norway, Abbvie, Allergan, Merz Pharma; SK is supported by Brain and Behavior Foundation, National institute on Ageing, BrightFocus Foundation, Brain Canada, Canadian Institute of Health Research, Centre for Ageing and Brain Health Innovation, Weston Brain Institute, Centre for Mental Health and Addiction Foundation and University of Toronto; DSP is supported by CIHR; ACR is supported by Canadian Institutes of Health Research Fellowship, Parkinson Society Canada, (NIH) National Institute on Deafness and Other Communication Disorders (1R21DC017255-01).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research ethics committees at all participating recruitment sites approved the ONDRI research protocol.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll ONDRI data, including but not limited to data used in this article, will be available to the scientific community through the Ontario Brain Institute later this year. Please see the Ontario Brain Institute website for more information. https://braininstitute.ca/